Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Organ Prolapse | 2 | 2017 | 42 | 1.320 |
Why?
|
| Postoperative Complications | 4 | 2017 | 645 | 0.800 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2018 | 4 | 0.750 |
Why?
|
| Nephrons | 1 | 2018 | 12 | 0.750 |
Why?
|
| Urinary Tract Infections | 3 | 2017 | 36 | 0.740 |
Why?
|
| Hemorrhage | 1 | 2018 | 105 | 0.690 |
Why?
|
| Disease Management | 1 | 2018 | 132 | 0.670 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 43 | 0.670 |
Why?
|
| Vagina | 1 | 2017 | 45 | 0.670 |
Why?
|
| Nephrectomy | 1 | 2018 | 116 | 0.660 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2017 | 210 | 0.660 |
Why?
|
| Surgical Mesh | 1 | 2017 | 48 | 0.650 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 67 | 0.650 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2017 | 42 | 0.650 |
Why?
|
| Pheochromocytoma | 1 | 2015 | 5 | 0.620 |
Why?
|
| Catecholamines | 1 | 2015 | 18 | 0.610 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 12 | 0.610 |
Why?
|
| Internship and Residency | 1 | 2017 | 271 | 0.540 |
Why?
|
| Urinary Tract | 1 | 2013 | 21 | 0.530 |
Why?
|
| Urologic Diseases | 1 | 2013 | 29 | 0.530 |
Why?
|
| Urinary Calculi | 1 | 2011 | 10 | 0.470 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2013 | 155 | 0.470 |
Why?
|
| Urine | 1 | 2011 | 59 | 0.450 |
Why?
|
| Ureter | 1 | 2011 | 41 | 0.440 |
Why?
|
| Mineral Oil | 1 | 2010 | 4 | 0.440 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2010 | 6 | 0.440 |
Why?
|
| Sclerosis | 1 | 2010 | 10 | 0.440 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 249 | 0.430 |
Why?
|
| Penis | 1 | 2010 | 39 | 0.420 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 251 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 443 | 0.400 |
Why?
|
| Middle Aged | 9 | 2018 | 11519 | 0.390 |
Why?
|
| Kidney | 1 | 2011 | 477 | 0.330 |
Why?
|
| Neoplasms | 1 | 2013 | 683 | 0.320 |
Why?
|
| Databases, Factual | 2 | 2017 | 327 | 0.310 |
Why?
|
| Retrospective Studies | 5 | 2017 | 2962 | 0.310 |
Why?
|
| Humans | 14 | 2018 | 29158 | 0.290 |
Why?
|
| Female | 9 | 2018 | 18849 | 0.290 |
Why?
|
| Prognosis | 2 | 2015 | 1426 | 0.210 |
Why?
|
| Aged | 4 | 2017 | 10010 | 0.200 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2175 | 0.190 |
Why?
|
| Adult | 6 | 2016 | 8705 | 0.180 |
Why?
|
| Tuberculosis, Urogenital | 1 | 2017 | 2 | 0.180 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2017 | 9 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 6 | 0.170 |
Why?
|
| Cystocele | 1 | 2017 | 4 | 0.170 |
Why?
|
| Male | 7 | 2017 | 18549 | 0.170 |
Why?
|
| Hernia | 1 | 2017 | 13 | 0.170 |
Why?
|
| Pelvic Floor | 1 | 2017 | 17 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2013 | 2028 | 0.170 |
Why?
|
| Uterine Prolapse | 1 | 2017 | 22 | 0.170 |
Why?
|
| Reoperation | 1 | 2017 | 165 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2017 | 103 | 0.160 |
Why?
|
| Young Adult | 2 | 2015 | 2425 | 0.160 |
Why?
|
| Nephrolithiasis | 1 | 2016 | 2 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 510 | 0.160 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2015 | 2 | 0.160 |
Why?
|
| Dizziness | 1 | 2015 | 8 | 0.160 |
Why?
|
| Vertigo | 1 | 2015 | 3 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 49 | 0.150 |
Why?
|
| Bioengineering | 1 | 2015 | 70 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2017 | 931 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 184 | 0.130 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 185 | 0.130 |
Why?
|
| Kidney Calculi | 1 | 2012 | 27 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3153 | 0.120 |
Why?
|
| Specific Gravity | 1 | 2011 | 1 | 0.120 |
Why?
|
| Hardness | 1 | 2011 | 5 | 0.120 |
Why?
|
| Magnesium | 1 | 2011 | 19 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 468 | 0.120 |
Why?
|
| Potassium | 1 | 2011 | 34 | 0.120 |
Why?
|
| Sodium | 1 | 2011 | 36 | 0.120 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2011 | 3 | 0.120 |
Why?
|
| Nitrofurantoin | 1 | 2011 | 3 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 558 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2015 | 907 | 0.120 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 78 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 320 | 0.120 |
Why?
|
| Creatinine | 1 | 2011 | 179 | 0.110 |
Why?
|
| Survival Rate | 1 | 2013 | 855 | 0.110 |
Why?
|
| Laos | 1 | 2010 | 3 | 0.110 |
Why?
|
| Infusions, Subcutaneous | 1 | 2010 | 9 | 0.110 |
Why?
|
| Men's Health | 1 | 2010 | 10 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 549 | 0.110 |
Why?
|
| Plant Preparations | 1 | 2009 | 24 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 61 | 0.100 |
Why?
|
| Antioxidants | 1 | 2009 | 113 | 0.100 |
Why?
|
| Urinary Bladder | 1 | 2010 | 170 | 0.090 |
Why?
|
| Cholesterol | 1 | 2009 | 245 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 277 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 931 | 0.080 |
Why?
|
| Tissue Engineering | 1 | 2010 | 604 | 0.070 |
Why?
|
| Adolescent | 1 | 2011 | 3176 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2009 | 790 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1096 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 175 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2015 | 30 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 533 | 0.040 |
Why?
|
| Risk Factors | 2 | 2016 | 3708 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2015 | 151 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2015 | 163 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 234 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 209 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2012 | 6 | 0.030 |
Why?
|
| Gases | 1 | 2012 | 7 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 2010 | 19 | 0.030 |
Why?
|
| Seeds | 1 | 2009 | 9 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 93 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2009 | 46 | 0.030 |
Why?
|
| Pregnancy | 1 | 2012 | 749 | 0.030 |
Why?
|
| Regeneration | 1 | 2010 | 164 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2009 | 179 | 0.020 |
Why?
|
| Stem Cells | 1 | 2010 | 288 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2010 | 382 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2009 | 896 | 0.020 |
Why?
|